HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026
Oral presentation and Booth L221 to connect HCB101 clinical development, FBDB™ platform expansion, and global collaboration opportunities
[Taipei, Shanghai, San Francisco | July 13, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-related diseases, today announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan.
HanchorBio comes to BIO Asia–Taiwan following a period of progress across clinical development, regulatory strategy, scientific collaboration, global partnering, and capital-market engagement. Together, these activities reflect a clear development model: establish a strong clinical anchor, learn from the biology emerging around it, expand through rational combinations, and translate those learnings into the next generation of multi-functional immunotherapies.
Immunity was never one-dimensional. Neither are we.
That belief shapes how HanchorBio develops medicines: start with evidence, follow the biology, and build what comes next.
Recent Momentum Across Clinical Development, Regulatory Strategy, and Collaboration
HCB101, HanchorBio’s engineered SIRPα-IgG4 Fc fusion protein, serves as the Company’s lead clinical anchor and is being developed as a potential myeloid-enhancing immune backbone for rational combination therapy.
Recent clinical data presented at the JCA–AACR Special Joint Conference in Kyoto provided additional evidence in gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma. Second-line gastric/GEJ cancer remains the lead development setting for HCB101, while emerging clinical and translational learnings are guiding the evaluation of selected expansion opportunities in tumor settings where myeloid biology, immune exclusion, and treatment resistance may play important roles.
The Company’s recent FDA Type C interaction further clarified the next stage of HCB101 development in second-line gastric/GEJ cancer, supporting continued dose and schedule optimization in combination with ramucirumab and paclitaxel, followed by a planned randomized Phase 2b lead-in strategy toward confirmatory development.
In parallel, HanchorBio is extending its strategy through biology-driven combinations. The Company’s recently announced strategic MOU with InxMed to explore complementary approaches to overcoming tumor microenvironment barriers in difficult-to-treat solid tumors.
Bringing the Strategy Together at BIO Asia–Taiwan
At BIO Asia–Taiwan, HanchorBio will bring these elements together through both scientific presentation and direct engagement with potential partners, collaborators, and investors.
On July 17, 2026, Wenwu Zhai, Ph.D., Chief Scientific Officer of HanchorBio, will deliver an oral presentation titled “Redefining Immuno-Oncology Through Multi-Functional Fc-Based Designer Biologics (FBDB) Platform.”
The presentation will describe HanchorBio’s approach to designing multi-functional biologics that bring complementary immune mechanisms together within a single molecular architecture, as well as the relationship between the Company’s clinical programs and its broader FBDB™ platform strategy.
Throughout the conference, HanchorBio will also exhibit at Booth L221, where the Company will showcase the HCB101 development strategy, its broader clinical pipeline, next-generation FBDB™ programs, and opportunities for licensing, combination development, and co-development.
Extending Global Engagement from the United States to Asia
The discussions HanchorBio brings to BIO Asia–Taiwan did not begin in Taipei.
In recent weeks, the Company has been engaging different parts of the global biotechnology ecosystem around a central question: how can a clinically informed myeloid strategy become a broader immunotherapy platform?
At BIO International 2026, HanchorBio’s business development team engaged with global biotechnology, pharmaceutical, and strategic partners. In parallel, Company leadership met with institutional investors and capital-market participants in New York and Boston to discuss HanchorBio’s clinical anchor-to-platform strategy and global development plans.
These conversations have also reinforced the importance of distinguishing HanchorBio’s strategy from first-generation CD47 drug development. The Company is building from a differentiated SIRPα-based clinical anchor, applying disciplined clinical and regulatory development, and using emerging evidence to guide rational combinations and next-generation multi-axis biologics.
BIO Asia–Taiwan now brings these threads together: new clinical evidence, a clearer regulatory path, biology-driven collaboration, global partnering, and U.S. capital-market engagement—at home, for a company building globally.
From Clinical Anchor to Platform Expansion
HanchorBio’s strategy begins with HCB101, but it does not end there.
Clinical and translational learnings from HCB101 are informing the Company’s broader FBDB™ platform strategy. Programs including HCB301 and HCB303 extend the approach toward multi-axis immunotherapy, while additional programs explore the relevance of myeloid biology beyond oncology.
Clinical anchor → rational expansion → platform optionality.
“BIO Asia–Taiwan comes at the right moment for HanchorBio,” said Scott Liu, Ph.D., Founder and Chairman of HanchorBio. “Recent progress across clinical development, regulatory planning, combination strategy, and global engagement has brought greater clarity to how we build from here. HCB101 is our clinical anchor. FBDB™ is our platform engine. Collaboration is how we expand the opportunity.”
“With our roots in Taiwan and building globally. BIO Asia–Taiwan gives us an important home-market platform to connect the clinical evidence we are generating, the biology we are learning from, and the partnerships that can help us move faster. Immunity was never one-dimensional. We believe the next generation of immunotherapy should be designed with that reality in mind.”
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies based on a fundamental belief: immunity is not one-dimensional, and the medicines designed to harness it should not be either.
Rooted in Taiwan with operations in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is advancing a pipeline of immunotherapies for oncology and immune-mediated diseases. The Company’s proprietary Fc-Based Designer Biologics (FBDB™) platform enables the design of multi-functional biologics that bring complementary immune mechanisms together within a single molecular architecture.
HanchorBio’s clinical pipeline is anchored by HCB101, an engineered SIRPα-IgG4 Fc fusion protein designed to restore macrophage-mediated antitumor activity and enable rational combination strategies. Clinical and translational learnings from HCB101 inform the Company’s broader platform expansion, including multi-axis immunotherapies and programs beyond oncology.
Listed on the Taiwan Stock Exchange Innovation Board (TWSE: 7827), HanchorBio is advancing its clinical development, regulatory strategy, and global partnerships from a foundation built in Taiwan and designed for global development.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions and decisions, protocol development, execution of collaboration, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.